# Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers

> **NCT06837077** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 46 (actual)

## Conditions studied

- Hypercholesterolemia and Hyperlipidemia

## Interventions

- **DRUG:** SHR-1209 single-site subcutaneous injection
- **DRUG:** SHR-1209 multiple-site subcutaneous injections

## Key facts

- **NCT ID:** NCT06837077
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-14
- **Primary completion:** 2025-06
- **Final completion:** 2025-07
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06837077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06837077, "Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06837077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*